higher-dose (HD) ICS in combination with a long-acting beta-agonist (LABA)	doses suggested in the practice guidelines (GD) or to receive GD therapy alone	dysphonia, headache , tremor, and hoarseness	18825	19040	dysphonia (3.2% in the HD group versus 2.8% in the GD group, P = 0.63), headache (2.1% versus 2.4%, respectively, P = 0.59), tremor (3.4% versus 3.7%, P = 0.71), and hoarseness of voice (4.2% versus 3.8%, P = 0.51).
higher-dose (HD) ICS in combination with a long-acting beta-agonist (LABA)	doses suggested in the practice guidelines (GD) or to receive GD therapy alone	Daily inhaled corticosteroid (ICS) consumption	18644	18786	Daily ICS consumption in the HD and GD groups was not significantly different (736 ± 219.7 μg versus 663.1 ± 267.2 μg, respectively P = 0.17).
higher-dose (HD) ICS in combination with a long-acting beta-agonist (LABA)	doses suggested in the practice guidelines (GD) or to receive GD therapy alone	the mean number of asthma-free days during the study	16599	16763	further, the mean number of asthma-free days during the study was greater in the HD group than in the GD group (82.4 ± 26.5 days versus 69.2 ± 24.3 days, P = 0.02).
higher-dose (HD) ICS in combination with a long-acting beta-agonist (LABA)	doses suggested in the practice guidelines (GD) or to receive GD therapy alone	dysphonia, headache , tremor, and hoarseness	18787	19040	Frequently reported side effects were dysphonia (3.2% in the HD group versus 2.8% in the GD group, P = 0.63), headache (2.1% versus 2.4%, respectively, P = 0.59), tremor (3.4% versus 3.7%, P = 0.71), and hoarseness of voice (4.2% versus 3.8%, P = 0.51).
higher-dose (HD) ICS in combination with a long-acting beta-agonist (LABA)	doses suggested in the practice guidelines (GD) or to receive GD therapy alone	forced expiratory volume in one second (FEV1)	1278	1467	The increase in FEV1 from baseline was greater in the HD group than in the GD group, especially during the first month of treatment (304 ± 49 mL versus 148 ± 39 mL, respectively, P = 0.01).
higher-dose (HD) ICS in combination with a long-acting beta-agonist (LABA)	doses suggested in the practice guidelines (GD) or to receive GD therapy alone	the mean number of asthma-free days during the study	16608	16763	the mean number of asthma-free days during the study was greater in the HD group than in the GD group (82.4 ± 26.5 days versus 69.2 ± 24.3 days, P = 0.02).
higher-dose (HD) ICS in combination with a long-acting beta-agonist (LABA)	doses suggested in the practice guidelines (GD) or to receive GD therapy alone	Numbers of patients with completely or well controlled asthma	1468	1624	Numbers of patients with completely or well controlled asthma were higher in the HD group than in the GD group (92.1% versus 81.1%, respectively, P = 0.03).
